Impact of Structural Biology in an Increasingly Fast-Paced Drug Discovery Environment

• Addressing the perceived mismatch between rapid AI-driven discovery cycles and slower experimental structural biology workflows
• Ensuring structural biology remains a critical decision-making tool rather than a downstream support function
• Integrating structural biology, computational chemistry, and AI/ML teams to drive confident discovery decisions
• Lessons from building cross-functional structural biology capabilities within a modern pharma organization

Speakers:

Ann Boriack-Sjodin

Executive Director and Global Head of Structural Biology

Takeda Pharmaceutical